According to the official website of the State Food and Drug Administration, the national conference on drug supervision and administration was held in Beijing on January 5. The meeting pointed out that to do a good job in drug regulation this year, we should firmly promote the modernization of Chinese drug regulation, continue to strengthen the bottom line of drug safety, deepen the reform of drug regulation, improve the efficiency of drug regulation, effectively ensure the safety and effectiveness of people's drug use, and support the high-quality development of the pharmaceutical industry. The meeting made arrangements for drug supervision in 2023. First, we should stick to the principle of integrity and firmly hold the bottom line of drug safety. Service and guarantee the epidemic prevention and control in the new stage, strengthen the quality supervision of epidemic prevention drugs and equipment, support the production and supply of key epidemic prevention drugs and equipment, and continue to do a good job in emergency review and approval; Promote the normalization of drug safety special rectification with a long-term mechanism, and effectively crack down on illegal and criminal acts; Continuously improve vaccine management system to ensure vaccine quality and supply; Strengthen the quality and safety supervision of key varieties, adhere to "zero tolerance" for product quality problems, and continue to strengthen online sales supervision; We will comprehensively strengthen the investigation and resolution of potential risks, comprehensively use various means to strengthen safety supervision, and improve the drug alert and emergency management system. Second, reform and innovation to promote high-quality development of the pharmaceutical industry. Promote the creation of a rainforest type medical innovation ecology, speed up the listing of new and good drugs, promote the research and development of high-end innovative medical devices, release the dividend of cosmetic review and approval reform, and stimulate regional medical innovation vitality; Promote the inheritance and innovative development of traditional Chinese medicine, improve the regulatory system of traditional Chinese medicine, improve the review and approval mechanism of traditional Chinese medicine, and strengthen international exchange and cooperation of traditional medicine; We will continue to release the dividend of "deregulation, regulation and service" reform, improve "Internet plus" government services, expand the promotion and application of enterprise related electronic licenses, and further optimize the business environment. Third, based on the long-term, comprehensively improve the drug regulatory capacity. We will improve the drug regulatory quality management system, the regulatory system, the standard system, and the science and technology support system, strengthen the construction of technical support capacity, vigorously develop smart supervision and regulatory science, promote higher levels of openness and higher quality international cooperation, and accelerate the modernization of the drug regulatory system and regulatory capacity. (Outlook New Times)
Edit：qihang Responsible editor：xinglan
Source：people.cn
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com
Recommended Reading Change it 
Home
